Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 1
1981 2
1983 2
1985 1
1986 1
1987 5
1988 3
1989 5
1990 12
1991 14
1992 7
1993 8
1994 9
1995 10
1996 11
1997 7
1998 6
1999 10
2000 8
2001 5
2002 6
2003 6
2004 7
2005 3
2006 4
2007 4
2008 11
2009 8
2010 3
2012 4
2013 4
2014 2
2015 2
2016 3
2017 4
2018 3
2019 5
2020 1
2021 3
2022 3
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

207 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of Propranolol, Bisoprolol, and Pyridostigmine for Postural Tachycardia Syndrome: a Randomized Clinical Trial.
Moon J, Kim DY, Lee WJ, Lee HS, Lim JA, Kim TJ, Jun JS, Park B, Byun JI, Sunwoo JS, Lee ST, Jung KH, Park KI, Jung KY, Kim M, Lee SK, Chu K. Moon J, et al. Neurotherapeutics. 2018 Jul;15(3):785-795. doi: 10.1007/s13311-018-0612-9. Neurotherapeutics. 2018. PMID: 29500811 Free PMC article. Clinical Trial.
Patients were randomly allocated to 4 treatment groups (Group 1: propranolol; Group 2: bisoprolol; Group 3: propranolol + pyridostigmine; Group 4: bisoprolol + pyridostigmine). The orthostatic intolerance questionnaire (OIQ), Beck depression inventory-II (BDI-II), a …
Patients were randomly allocated to 4 treatment groups (Group 1: propranolol; Group 2: bisoprolol; Group 3: propranolol + pyridostigmine …
Neurovascular Dysregulation and Acute Exercise Intolerance in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Randomized, Placebo-Controlled Trial of Pyridostigmine.
Joseph P, Pari R, Miller S, Warren A, Stovall MC, Squires J, Chang CJ, Xiao W, Waxman AB, Systrom DM. Joseph P, et al. Chest. 2022 Nov;162(5):1116-1126. doi: 10.1016/j.chest.2022.04.146. Epub 2022 May 6. Chest. 2022. PMID: 35526605 Clinical Trial.

RESULTS: Twenty-three subjects were assigned to receive pyridostigmine and 22 to receive placebo. The peak Vo(2) increased after pyridostigmine but decreased after placebo (13.3 13.4 mL/min vs -40.2 21.3 mL/min; P < .05). ...INTERPRETATION: Pyridostigmine

…
RESULTS: Twenty-three subjects were assigned to receive pyridostigmine and 22 to receive placebo. The peak Vo(2) increased after p …
Pyridostigmine, diethyltoluamide, permethrin, and stress: a double-blind, randomized, placebo-controlled trial to assess safety.
Roy MJ, Kraus PL, Seegers CA, Young SY, Kamens DR, Law WA, Cherstniakova SA, Chang DN, Cooper JA, Sato PA, Matulich W, Krantz DS, Cantilena LR, Deuster PA. Roy MJ, et al. Mayo Clin Proc. 2006 Oct;81(10):1303-10. doi: 10.4065/81.10.1303. Mayo Clin Proc. 2006. PMID: 17036555 Clinical Trial.
OBJECTIVE: To determine whether short-term human exposure to pyridostigmine bromide, diethyltoluamide, and permethrin, at rest or under stress, adversely affects short-term physical or neurocognitive performance. ...Physical and neurocognitive outcome measures and s …
OBJECTIVE: To determine whether short-term human exposure to pyridostigmine bromide, diethyltoluamide, and permethrin, at rest …
Delayed orthostatic hypotension: Severity of clinical symptoms and response to medical treatment.
Byun JI, Moon J, Kim DY, Shin H, Sunwoo JS, Lim JA, Kim TJ, Lee WJ, Lee HS, Jun JS, Park KI, Lee ST, Jung KH, Jung KY, Kim M, Lee SK, Chu K. Byun JI, et al. Auton Neurosci. 2018 Sep;213:81-85. doi: 10.1016/j.autneu.2018.06.005. Epub 2018 Jun 28. Auton Neurosci. 2018. PMID: 30005744 Clinical Trial.
This study aimed to compare the symptom severity between classic and delayed OH and evaluate the efficacy of midodrine or pyridostigmine in patients with delayed OH. METHODS: This was an adjunctive study of previously reported randomized, open-label clinical trials evaluat …
This study aimed to compare the symptom severity between classic and delayed OH and evaluate the efficacy of midodrine or pyridostigmine …
Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension.
Byun JI, Moon J, Kim DY, Shin H, Sunwoo JS, Lim JA, Kim TJ, Lee WJ, Lee HS, Jun JS, Park KI, Lee ST, Jung KH, Jung KY, Lee SK, Chu K. Byun JI, et al. Neurology. 2017 Sep 5;89(10):1078-1086. doi: 10.1212/WNL.0000000000004340. Epub 2017 Aug 9. Neurology. 2017. PMID: 28794253 Clinical Trial.
In total, 87 patients with symptomatic neurogenic OH were enrolled and randomized to receive 1 of 3 treatments: midodrine only, pyridostigmine only, or midodrine + pyridostigmine. The patients were followed up at 1 and 3 months after treatment. ...Orthostatic sympto …
In total, 87 patients with symptomatic neurogenic OH were enrolled and randomized to receive 1 of 3 treatments: midodrine only, pyridosti …
Synergistic Pressor Effect of Atomoxetine and Pyridostigmine in Patients With Neurogenic Orthostatic Hypotension.
Okamoto LE, Shibao CA, Gamboa A, Diedrich A, Raj SR, Black BK, Robertson D, Biaggioni I. Okamoto LE, et al. Hypertension. 2019 Jan;73(1):235-241. doi: 10.1161/HYPERTENSIONAHA.118.11790. Hypertension. 2019. PMID: 30571543 Free PMC article. Clinical Trial.
We tested the hypothesis that pyridostigmine will potentiate the pressor effect of atomoxetine and improve orthostatic tolerance and symptoms in patients with severe autonomic failure. Twelve patients received a single oral dose of either placebo, pyridostigmine 60 …
We tested the hypothesis that pyridostigmine will potentiate the pressor effect of atomoxetine and improve orthostatic tolerance and …
A six-month randomized controlled trial of exercise and pyridostigmine in the treatment of fibromyalgia.
Jones KD, Burckhardt CS, Deodhar AA, Perrin NA, Hanson GC, Bennett RM. Jones KD, et al. Arthritis Rheum. 2008 Feb;58(2):612-22. doi: 10.1002/art.23203. Arthritis Rheum. 2008. PMID: 18240245 Free PMC article. Clinical Trial.
OBJECTIVE: A subset of fibromyalgia (FM) patients have a dysfunctional hypothalamic-pituitary-insulin-like growth factor 1 (IGF-1) axis, as evidenced by low serum levels of IGF-1 and a reduced growth hormone (GH) response to physiologic stimuli. There is evidence that pyridost …
OBJECTIVE: A subset of fibromyalgia (FM) patients have a dysfunctional hypothalamic-pituitary-insulin-like growth factor 1 (IGF-1) axis, as …
Pyridostigmine reduces mortality of patients with severe SARS-CoV-2 infection: A phase 2/3 randomized controlled trial.
Fragoso-Saavedra S, Núñez I, Audelo-Cruz BM, Arias-Martínez S, Manzur-Sandoval D, Quintero-Villegas A, Benjamín García-González H, Carbajal-Morelos SL, PoncedeLeón-Rosales S, Gotés-Palazuelos J, Maza-Larrea JA, Rosales-de la Rosa JJ, Diaz-Rivera D, Luna-García E, Piten-Isidro E, Del Río-Estrada PM, Fragoso-Saavedra M, Caro-Vega Y, Batina I, Islas-Weinstein L, Iruegas-Nunez DA, Calva JJ, Belaunzarán-Zamudio PF, Sierra-Madero J, Crispín JC, Valdés-Ferrer SI. Fragoso-Saavedra S, et al. Mol Med. 2022 Nov 8;28(1):131. doi: 10.1186/s10020-022-00553-x. Mol Med. 2022. PMID: 36348276 Free PMC article. Clinical Trial.
We aimed to determine if pyridostigmine decreases a composite outcome of invasive mechanical ventilation (IMV) and death in adult patients with severe COVID-19. ...The primary outcome occurred in 22 (23.4%) participants in the placebo group vs. 11 (11.7%) in the pyridos …
We aimed to determine if pyridostigmine decreases a composite outcome of invasive mechanical ventilation (IMV) and death in adult pat …
Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome.
Oh SJ, Kim DS, Head TC, Claussen GC. Oh SJ, et al. Muscle Nerve. 1997 Sep;20(9):1146-52. doi: 10.1002/(sici)1097-4598(199709)20:9<1146::aid-mus9>3.0.co;2-8. Muscle Nerve. 1997. PMID: 9270671 Clinical Trial.
In all patients, a liberal amount of pyridostigmine was used, while daily guanidine dose was kept below 1000 mg a day, and guanidine was given between pyridostigmine dosings. ...Thus, we conclude that low-dose guanidine therapy is relatively safe and effective for l …
In all patients, a liberal amount of pyridostigmine was used, while daily guanidine dose was kept below 1000 mg a day, and guanidine …
Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E. Procopio M, et al. Int J Obes Relat Metab Disord. 1995 Feb;19(2):108-12. Int J Obes Relat Metab Disord. 1995. PMID: 7735336 Clinical Trial.
We studied the GH response to GH-releasing hormone (GHRH) alone and combined with arginine or pyridostigmine, two substances likely to inhibit hypothalamic somatostatin release. ...CONCLUSIONS: Our results indicate that the GH releasable pool is reduced in obesity and, to …
We studied the GH response to GH-releasing hormone (GHRH) alone and combined with arginine or pyridostigmine, two substances likely t …
207 results